NCT04260438View on ClinicalTrials.gov

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 8, 2020

Primary Completion Date

June 15, 2020

Study Completion Date

June 24, 2020

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T

single oral administration under fed condition

DRUG

CKD-393 0.5/100/1000mg formulation 1 Tab. 1T

single oral administration under fed condition

DRUG

CKD-393 0.5/100/1000mg formulation 2 Tab. 1T

single oral administration under fed condition

Trial Locations (1)

Unknown

Korea University Anam Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT04260438 - Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects | Biotech Hunter | Biotech Hunter